(Q33726931)

English

Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

0 references

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

object named as

Erkki J O Soini

2

0 references

author name string

Taru A Hallinen

1

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Kari Eklund

3

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Kari Puolakka

4

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

publication date

25 January 2010

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

49

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

767-777

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838414

21 June 2018

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838414

21 June 2018

The widening mortality gap between rheumatoid arthritis patients and the general population

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838414

21 June 2018

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838414

21 June 2018

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838414

21 June 2018

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838414

21 June 2018

Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838414

21 June 2018

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838414

21 June 2018

Long-term cyclosporin continuation rates in rheumatoid arthritis patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838414

21 June 2018

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838414

21 June 2018

A 10 year follow up of parenteral gold therapy in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838414

21 June 2018

The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP425

21 January 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP425

21 January 2018

Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP425

21 January 2018

A systematic review of the role of bisphosphonates in metastatic disease

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP425

21 January 2018

Use of the Stanford Health Assessment Questionnaire in estimation of long-term productivity costs in patients with recent-onset rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP425

21 January 2018

Representing uncertainty: the role of cost-effectiveness acceptability curves

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP425

21 January 2018

Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI).

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP425

21 January 2018

Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP425

21 January 2018

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP425

21 January 2018

The effectiveness and toxicity of cyclosporin A in rheumatoid arthritis: longitudinal analysis of a population-based registry

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP425

21 January 2018

Costs, effects and C/E-ratios alongside a clinical trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2838414

30 October 2018

Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane

1 reference

https://pubmed.ncbi.nlm.nih.gov/20100793

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic consequences of the progression of rheumatoid arthritis in Sweden

1 reference

https://pubmed.ncbi.nlm.nih.gov/20100793

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/20100793

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20100793

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept

1 reference

https://pubmed.ncbi.nlm.nih.gov/20100793

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20100793

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug

1 reference

https://pubmed.ncbi.nlm.nih.gov/20100793

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quality of life measures: use and abuse

1 reference

https://pubmed.ncbi.nlm.nih.gov/20100793

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/RHEUMATOLOGY/KEP425

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33726931&oldid=1534391068"